Latest Dalton Pharma Services Stories
Dalton Pharma Services today announced that it has expanded it cGMP sterile powder filling capabilities as part of its ongoing focus of sterile manufacturing, supported by FedDev Ontario funding.
Dalton Pharma Services announces the launch of its new Steriles Made Simple(SM) Programs, designed to produce sterile liquid injectables for early phase clinical trials in as little as four months.
Dalton awarded funding from ISTPCanada as part of an international vaccine development project under the 2013 Canada-China Joint Initiative on Human Vaccine Research and Development program
Dalton Pharma Services signs agreement with GLyPharma Therapeutics Inc., to provide aseptic fill/finish services and analytical services for FE 203799 for cancer patients. Toronto,
Dalton announces the completion of a $2.5 million expansion of its sterile and aseptic filling capabilities. Toronto, Ontario (PRWEB) March 20, 2014
A Phase 1b clinical trial to evaluate Celgosivir as a treatment against Dengue Fever has opened for enrolment at the Singapore General Hospital.
Dalton will provide cGMP chemistry manufacturing, scale up, aseptic fill/finish services and analytical support for Clarity Toronto, Ontario (PRWEB) June 14,
Dalton Announces it has received a Good Laboratory Practices (GLP) certificate from The Standards Council of Canada (SCC) Toronto, Ontario (PRWEB) May 30, 2012
Dalton Announces Online Structure Search Capability Toronto, Ontario (PRWEB) December 30, 2011 Dalton Pharma Services, a privately owned Canadian pharmaceutical
Dalton Enters Into cGMP Vaccine and Conjugation Aseptic Fill Services Agreement with The Henry M.